STAMBP and Alzheimer disease: Both α-MSH and NDP-MSH (Langendonk et al. 2015) have additionally been shown to protect in models of other central nerve system (CNS) disorders after systemic administration, including ischemic stroke, spinal cord injury, traumatic brain injury, Alzheimer’s disease (AD), and other neuroinflammation-associated diseases like intracerebral hemorrhage (Giuliani et al. 2014; Leone et al. 2013; Mykicki et al. 2016; Schaible et al. 2013; Wu et al. 2019).